PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET

IntroductionThis study aimed to investigate the dynamics of programmed death-ligand 1 (PD-L1) expression, spatial heterogeneity, and binding affinity of FDA-approved anti-PD-L1 antibodies (avelumab and atezolizumab) in gastric cancer. Additionally, we determined how PD-L1 glycosylation impacts antib...

詳細記述

書誌詳細

主要な著者:	Dina Ibrahim, Cristina Simó, Emma L. Brown, Shayla Shmuel, Sandeep Surendra Panikar, Alex Benton, Rachel DeWeerd, Farrokh Dehdashti, Haeseong Park, Patrícia M. R. Pereira
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2024-06-01
シリーズ:	Frontiers in Immunology
主題:	PD-L1 N-glycosylation gastric tumors immunoPET avelumab atezolizumab
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1405485/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!